cp wire

CP Wire Articles

FDA Approves First Cancer Drug Under New Real Time Review Program
  • Kisqali approved under Real Time Oncology Review Program
  • One of two new programs intended to make the development of cancer drugs more effecient
  • Approval came less than one... read more
Wed, 07/18/18 - 01:20 pm
Cellectar Reports 33% Overall Response Rate in Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients
  • Observed responses to date show overall tumor reduction ranged from 60% to greater than 90%
  • Company is expanding trial cohort up to 30 additional patients
  • CLR 131 has orphan... read more
Wed, 07/18/18 - 09:58 am
Takeda and Ovid Therapeutics Expand Clinical Program for TAK-935/OV935 with New Studies in Rare Developmental and Epileptic Encephalopathies (DEE)
  • TAK-935/OV935 is a first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase
  • TAK-935/OV935 may potentially treat rare epilepsies by inhibiting CH24H to decrease 24HC levels... read more
Wed, 07/18/18 - 09:43 am
FDA Grants Priority Review and accepts BLA for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer
  • PDUFA target date is 1/18/19
  • Sacituzumab govitecan is an antibody drug conjugate (ADC)
  • If appproved it would be the first ADC approved for mTNBC
  • Company has another... read more
Wed, 07/18/18 - 09:27 am
[sponsored] Speaker Book - The App That Exposes Conflicts of Interest in the Pharmaceutical Industry

SPEAKER BOOK APP is the platform where patients advocates, doctors, and biotech investors can look at conflicts of interest in Pharma to understand what is going on under the surface of... read more

Tue, 07/17/18 - 03:25 pm

Pages